Shionogi awarded $375m from HHS for preventative Covid-19 injectable
Shionogi’s S-892216 is being developed as a pre-exposure prophylaxis (PrEP) drug for Covid-19. Credit: seksan Mongkhonkhamsao via Getty Images.
Covid-19
Petrovax announces positive results from long-CoV-III-21 trial of Longidaza for long-term pulmonary sequelae of COVID-19
Q3 2024 update: COVID-19 related private equity activity in the pharmaceutical industry
mRNA licensing agreements surge 800% amid GSK lawsuits
As mpox spreads, ‘national governments have a moral responsibility to help’
Novavax wins FDA emergency approval for updated Covid-19 vaccine
What is mpox and how big of a threat is it?
BioNTech exits PD-L1 development with Genmab as Q2 revenues drop
